Helen Davis

By halving infusion volumes for immunodeficiency patients, Takeda's experimental TAK-881 is not just treating a disease—it is giving people their time back.

Alpha Cognition is set to present compelling real-world data on ZUNVEYL, revealing how this novel prodrug could reduce psychotropic use in long-term care.

With over 700,000 annual deaths, liver cancer is a global crisis. Yet 60% of cases are preventable. We explore the gap between innovation and patient access.

At 95, William Shatner is fronting Audien Hearing's new campaign. But behind the celebrity endorsement lies a fierce battle for a $1.4 billion market.

Heavy menstrual bleeding drives 600,000 surgeries a year. Hemab Therapeutics aims to replace invasive treatments with a once-a-month injection.

A French biotech takes a critical step to industrialize a promising therapy for LCAT deficiency, navigating the high-stakes regulatory world of biologics.

An acquisition signals more than growth; it’s a strategic redesign of the clinical trial landscape, challenging giants and empowering innovation.

A San Diego biotech is advancing a device to clean the blood of disease-fueling particles. With early promise in cancer and a new path in Long COVID, can it navigate the financial realities of innovation?

Two years after a landmark rejection, the bid to approve MDMA-assisted therapy for PTSD is back. This is more than a resubmission; it's a test case for a new paradigm in medicine.

With late-stage trials underway and a cash runway into 2030, Trevi Therapeutics is accelerating its mission. But what does this mean for millions of unseen sufferers?

Evolent Health touts soaring revenues and a major oncology deal, yet falling profits and rising medical costs reveal a challenging road ahead. Can AI deliver the efficiency it needs?

After a corporate overhaul and a massive cash infusion, Faeth Therapeutics is pushing its multi-pronged cancer drug PIKTOR toward pivotal clinical data.

Curative Biotechnology secures a key U.S. patent for a metformin eye-drop, a novel approach that could transform treatment for macular degeneration.

Slate Medicines appoints Mark W. Hahn, a CFO known for steering biotechs to massive acquisitions, signaling a major strategic push for its next-gen therapy.

As home care agencies face a perfect storm of financial cuts and regulatory burdens, technology firms like Axxess are betting that AI is the key to survival.

With a new ADC expert as CMO, Corbus Pharmaceuticals is advancing its dual pipeline. This move signals a critical phase for its cancer drug and obesity therapy.

An award for an AI search tool seems routine, but Ask Ella signals a deeper rewiring of the life sciences industry, turning data drudgery into strategic speed.

ProQR's Axiomer platform achieves its first human validation, showing promise for rare pediatric liver diseases and signaling a major step for RNA editing.

Amity University and L&T Technology Services launch a Centre of Excellence to bridge India's critical EV skills gap, creating a new pipeline for innovation.

For decades, insomnia treatment meant risky sedatives. Now, a new class of drugs is revolutionizing sleep science, promising safer rest for millions.